REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
News

Sheba Study Indicates: Pfizer-BioNTech COVID-19 Vaccine Effective Against Omicron Variant

COVID-19 Vaccine Protects Against Severe Illness
According to a study conducted by Sheba Medical Center and the Israeli Ministry of Health, three doses of the Pfizer-BioNTech COVID-19 vaccine provide significant protection against the Omicron variant.

Following the emergence of the COVID-19 Omicron variant, many wondered if existing vaccines would provide adequate protection. A recent study conducted by Sheba Medical Center and the Israeli Ministry of Health attempted to address concerns.

The study evaluated the efficacy of existing COVID-19 vaccines against the Omicron variant and confirmed that receiving three doses of the Pfizer-BioNTech COVID-19 vaccine will provide significant protection against the Omicron variant, as results indicate that the vaccine prevents severe illness.

In contrast, the study found that two doses of the vaccine are not likely to be effective against the Omicron variant. Thus, an individual vaccinated only twice remains at high risk of contracting the variant and becoming seriously ill.

According to Prof. Gili Regev-Yochay, Head of the Infection Prevention and Control Unit at Sheba, who also led the study: “The findings emphasized the importance of increasing the vaccination rates as an effective and necessary measure to stop the spread of the virus.”

Related

Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More
Hemophilia research
News Sep 05.

New Sheba Study Indicates: Novel Treatment Sharply Reduces Bleed Rates Among Hemophilia Patients

Results indicate that a monthly treatment with Fitusiran significantly reduces bleed rates among both hemophilia A and B patients.
Read More